the stock almost doubled from the 30's to the 60's range, now it has taken an orderly path back to its support level, if the stock didnt have great potintial to break out of its past trading range, dont you think it would have fallen back to the 30's in a couple of days after ph3 release? it's been 12 trading days since the news release. i think it's holding up rather well
Both levels are depressed imo - .30 - .60 range ps. For a biotech with P3 commencing as planned, cash and no debt, this one is being held down for some reason. Between now and end of March, the only catalyst to get this one headed in the right direction might be a partnership if that is even on the table. Otherwise, looks like a flatline to me. Finally, isn't it interesting that other cos with recent P2 announcements/updates and perhaps much more uncertainty trade at much higher valuations from a market cap perspective? Something definitely isn't "right" here... Just my opinion, do your own dd.